SAGE Therapeutics (SAGE) and Biogen (BIIB) Report Topline Results from Phase 2 KINETIC 2 Study of SAGE-324

Goldman Sachs Reiterates Buy Rating on Biogen (BIIB), 'We next await the August 1 earnings call'

July 26, 2024 12:18 PM EDT

Goldman Sachs analyst Salveen Richter reiterated a Buy rating and $342.00 price target on Biogen (NASDAQ: BIIB)

The analyst comments "The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion for BIIB/Eisais Leqembi, stating that the slowing of cognitive decline in treated patients does not outweigh the safety risks... More

Biogen (BIIB) PT Lowered to $307 at Piper Sandler

July 26, 2024 10:40 AM EDT

Piper Sandler analyst Christopher Raymond lowered the price target on Biogen (NASDAQ: BIIB) to $307.00 (from $313.00) while maintaining a Overweight rating.

The analyst comments "Conclusion: Remain OW on BIIB shares despite news this morning that the EMAs Committee for Medicinal Products for Human... More

Biogen (BIIB) PT Lowered to $282 at RBC Capital

July 26, 2024 10:10 AM EDT

RBC Capital analyst Brian Abrahams lowered the price target on Biogen (NASDAQ: BIIB) to $282.00 (from $303.00) while maintaining a Outperform rating.

The analyst comments "Our analysis suggests a 20% historical success rate for drugs CHMP re-examines; looking at prior examples over the past 10 years, we... More

Sage Therapeutics stock sinks after drug study failed

July 24, 2024 8:15 AM EDT

SAGE Therapeutics (NASDAQ: SAGE) stock price dropped significantly pre-market Wednesday after the company, alongside partner Biogen, announced disappointing results from a late-stage clinical trial for its drug SAGE-324 (BIIB124) for essential tremor (ET).

The Phase 2 KINETIC 2 study failed to meet its primary endpoint, which measured improvement in upper limb tremors. Additionally, no... More

SAGE Therapeutics (SAGE) Falls 24% After Phase 2 KINETIC 2 Study of SAGE-324 Fails

July 24, 2024 7:43 AM EDT

SAGE Therapeutics (NASDAQ: SAGE) Falls 24% After Phase 2 KINETIC 2 Study of SAGE-324 Fails

- SAGE-324 (BIIB124) did not demonstrate a statistically significant dose-response relationship on the primary endpoint in participants with essential tremor- No statistically significant differences were demonstrated between any dose of SAGE-324 and... More